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Abstract
Background
Measuring viral DNA methylation in human papillomavirus (HPV) infected women showed
promise for accurate detection of high-grade cervical lesions and cancer. Methylation status
has been widely investigated for HPV16, sporadically for other HPV types.
Methods
Objective of this methodological study was to set up molecular methods to test the methyla-
tion levels in the twelve oncogenic HPV types by pyrosequencing, minimizing the number of
HPV type-specific PCR protocols. Target CpGs were selected on the HPV L1 (two regions,
L1 I and L1 II) and L2 genes.
Study samples included DNA stored at Turin, Italy, purified by cervical cells collected in
Standard Transport Medium or PreservCyt from women who participated in two studies (N =
126 and 140) nested within the regional organized screening programme.
PCR consensus primers were designed by PyroMark Assay Design software to be suit-
able for amplification of many different oncogenic HPV types.
Results
Generation of consensus primers was successful for L1 I and II regions, unsuccessful for L2
region, for which HPV type-specific primers remained necessary. The difference between
replicated tests on the same sample was4% in 88%, 77% and 91% of cases when target-
ing the L1 I, L1 II and L2 regions, respectively. The corresponding intra-class correlation
coefficients (ICC) were 0.94, 0.87 and 0.97 respectively. When comparing methylation
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Conclusions
The proposed protocols, applying consensus primers suitable to amplify the oncogenic HPV
types and minimize the number of PCR reactions, represent a promising tool to quantify
viral methylation in women positive for any high risk HPV type.
Impact
Potential application of these methylation protocols in screening settings can be explored to
identify women with high probability of progression to high grade lesions.
Introduction
Persistent infection by oncogenic high risk human papillomavirus (hrHPV) types drives the
development of high-grade cervical intraepithelial neoplasia (hgCIN) which may, if untreated,
progress to invasive cervical cancer.
In hrHPV positive women, measuring DNA methylation in the HPV genome has shown
promise for accurate detection of hgCIN and cancer [1–9]. The HPV genome is poorly methyl-
ated at the time of cell infection and it does not harbour methylating enzymes but can be
affected by methylation events driven by the host cell DNA methyltransferases [10,11]. At
present, methylation status has been investigated mostly in HPV16 and to a lesser extent in the
remaining oncogenic HPV types [2,3,12–15]. Most studies employed whole genome sequenc-
ing, with the aim of assessing the methylation status of the majority of viral CpGs, which are
widespread along the HPV genome and poorly clustered in islands [16]. This approach pro-
vided evidence that methylation events, which represent a defence mechanism by the host cell
to silence viral DNA [17], largely involve most of the viral CpGs, although single CpG sites can
be methylated at different levels. Mirabello and collaborators [4] showed indeed that most of
the CpG sites in the HPV16 genome appear to be methylated in a coordinated fashion. Previ-
ous results suggested that selected CpGs, located in the HPV late regions L1 and L2, are associ-
ated to current or future high grade CIN detection [18,19]. In particular, this association
resulted very strong for some CpGs located in the L1 and L2 capsid genes consistently across
studies [2,4,5,13–15,20,21]. To our knowledge, however, among these studies, only a recent
one [15] focused on the evaluation in cervical scrape samples of HPV methylation levels in all
the twelve oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) [22], by using a
next generation sequencing approach.
A commonly used method for assessing methylation status of DNA is pyrosequencing. This
entails a preliminary amplification of bisulfite-modified DNA, until now performed by type-
specific primers. The present paper reports about the development of consensus primers for
multiple HPV genotypes and their use to evaluate methylation status of the L1 and L2 viral
regions by pyrosequencing. This approach is able to minimize the number of PCR protocols
needed to investigate the methylation status in the twelve hrHPV types.
We report here about its development and analytical validation, including the reproducibil-
ity of methylation values on the same sample and the consistency of such values with those
obtained by type-specific primers. The association of such values with the current or future
detection of high-grade cervical intraepithelial neoplasia (CIN) is not included. This would
take as itself the space of another full article.
HPV methylation by consensus primers-driven pyrosequencing
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Methods
General study design
CpG sites were selected for HPV16, based on their location in the L1 or L2 regions and the
strong reported association of their methylation with hgCIN occurrence. For the remaining
hrHPV types the CpGs closest to those selected for HPV16 were identified. Type-specific and
consensus primers for the defined sequences were generated and checked to avoid artefact
sequences. PCR and pyrosequencing conditions were optimised. Consensus primers were vali-
dated, under such optimised conditions, as for the reproducibility of the estimated methylation
and its consistency with that obtained by applying type-specific primers.
Study samples
We used two series of DNA samples, obtained from women participating to: (1) the NTCC
study (a randomised controlled trial which provided evidence of greater efficacy of HPV-
based than cytology-based screening in preventing invasive cervical cancer [23,24]) and (2) the
HPV pilot project, subsequently conducted to evaluate the routine application of HPV based
screening [25]. Both studies were nested within the organized screening programme of Turin,
Italy. Both had been approved by the local Ethical Committee of Turin (Comitato Etico Intera-
ziendale A.O.U. Città della Salute e della Scienza di Torino—A.O. Ordine Mauriziano—A.S.L.
TO1) along with the storage of residual cervical cell samples for future molecular investigations
after written informed consent. DNA had been extracted from cervical cell samples taken at
enrolment through the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to man-
ufacturer instructions and genotyped for hrHPV types by the Digene HPV genotyping RH kit
(Qiagen) as previously described [26].
Only samples from HPV positive women with infection by a single hrHPV type at the
screening test were included.
DNA samples from the HPV pilot project (N = 126) were used to develop and set up the
novel methylation assays. Ten to thirteen samples for each hrHPV type were randomly
retrieved from storage. They had been extracted from cervical scrapes collected in STM (Stan-
dard Transport Medium, Qiagen) and had been positive to the Hybrid Capture 2 (HC2, Qia-
gen) HPV screening test.
DNA samples from the NTCC trial (Turin centre) (N = 140) were used to assess the repro-
ducibility of the newly developed quantitative methylation assays. They had been extracted
from cervical scrapes collected either in STM or in PreservCyt (Hologic/Gen-Probe, San
Diego, CA) and had been HC2 positive. As they had been already used to analyse methylation
status in selected host cell genes (data under evaluation) residual bisulfite modified DNA
stored at -80˚C was used for the current reproducibility evaluation, with each sample tested
twice. For each hrHPV type five to twenty-one samples were randomly retrieved from bisulfite
modified DNA storage.
CpG selection
As methylation events had been suggested to involve most of the HPV CpGs in hgCIN [2–
7,11], we skipped the whole viral genome sequencing and focused on specific CpG sites
reported with statistically significant odds ratios (ORs).
For all the HPV oncogenic types the CpG sites to analyse were selected on the L1 and L2
capsid genes on the basis of the following considerations: i) in some HPV types (e.g. HPV18)
methylation events poorly involve other viral genes, such as the URR (untranslated regulatory
region) and E6 [27]; ii) the results of the studies on the association between methylation of
HPV methylation by consensus primers-driven pyrosequencing
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URR and hgCIN were controversial [9,28]; iii) HPV late genes show higher sequence homol-
ogy among types, which could make the generation of consensus primers easier. Furthermore,
selection was focused on CpG sites that had been reported to be hypermethylated in associa-
tion with hgCIN (with OR2 or p<0.05) in at least two published studies.
Reference sequences and CpG positions for each HPV type were found at www.ncbi.nlm.
nih.gov web site and are listed in Table 1.
HPV16 genome sequence was used as reference and three regions, hereafter denoted as L1 I
(CpG 5601, 5606, 5609, 5616) [4,5,13–15,20,21], L1 II (CpG 6457) [4,14] and L2 (CpG 4261)
[2,4,5,15,20], were selected.
For non-HPV16 oncogenic types, CpG sites were identified through the multiple sequence
alignment tool Clustal Omega (www.ebi.ac.uk/ Tools/msa/clustalo/), which allowed visualiz-
ing the sequence homology and identifying, along each HPV type sequence, the CpG closest to
each selected HPV16 CpG. Sequence alignment was performed following conversion to bisul-
fite modified sequences by the PyroMark Assay Design 2.0. software (Qiagen). The correct for-
mat to fit Clustal Omega tool was obtained by the Emboss Seqret software (www.ebi.ac.uk/
Tools/sfc/emboss seqret).
For each hrHPV type, the CpGs aligned to the selected HPV16 CpGs were chosen for analy-
sis. In case of imperfect alignment, nearby CpGs were selected. When all twelve hrHPV
sequences were aligned homology was poor. Substantial improvement in sequence homology
was obtained by grouping types in two families, mostly based on their phylogenetic affinity
and hereafter defined as “16 family” (HPV 16, 31, 33, 35, 52, 56, 58) and “18 family” (HPV 18,
39, 45, 51, 59).
Generation of primers
Primers for the selected target regions L1 I, L1 II and L2 of the “16 family” and “18 family”
were designed through the PyroMark Assay Design 2.0 software (Qiagen). Software stringent
criteria, such as the mandatory requirement to avoid primer overlap of CpG sites and, when
possible, to avoid homopolymers and the generation of amplicons longer than 300 bp, were
Table 1. Reference sequences for the twelve oncogenic HPV types and CpG positions.
HPV type Reference sequence CpG position
L1 Ia L1 IIb L2
16 NCBI: NC_001526.2 5601 5606 5609 5616 6457 4261
18 GenBank: KC470224.1 (L1) EF202151.1 (L2) 5599 5616 6433 4268
31 GenBank: J04353.1 5518 5521 5524 5530 6498 4195
33 GenBank: M12732.1 5557 5560 5566 5572 6409 4234
35 GenBank: M74117.1 5540 5543 5546 5553 6519 4208
39 GenBank: KC470245.1 5682 6513 4301
45 GenBank: KC470260.1 5620 5636 6463 4260
51 GenBank: GQ487711.1 (L1) KF436879.1 (L2) 13 848 4158
52 GenBank: HQ537750.1 5613 5616 5622 5628 6450 4290
56 GenBank: EF177179.1 5561 5567 5570 5576 6475 6496 4247
58 GenBank: GI222386 5606 5609 5615 5621 6447 6458 4268
59 GenBank: KC470266.1 5618 6452 4255
a Some HPV types do not have all the four CpGs found in the HPV16 reference sequence, but only two (HPV18, 45) or one (HPV39, 51, 59)
b Some HPV types (HPV56, 58) have two CpGs close to the CpGs selected in HPV16 sequence. For these types the average between the methylation values of two CpGs
can be considered.
https://doi.org/10.1371/journal.pone.0194619.t001
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taken into account. Sets of three primers, two for the amplification of the sequence that con-
tains the selected CpGs and one for its sequencing, were generated for each hrHPV type.
Quality checks were performed throughout pyrosequencing to avoid artefact sequences:
either the amplicon alone, or the biotinylated primer or the sequencing primer were combined
with the annealing buffer and tested, expecting no sequencing. For the same purpose, each bio-
tinylated primer was combined with the sequencing primer. Moreover, primers were tested on
hrHPV negative samples to assess their specificity for the HPV genome and exclude cross-
reaction with host cell genome. Primers were first tested on samples containing the specific
hrHPV type. Further, within each HPV family, each forward primer was coupled with each
reverse primer and tested for amplification of all the types included in the family, in the aim to
identify potential consensus primers favoured by sequence homology. Similarly, each sequenc-
ing primer was tested by pyrosequencing with amplicons from all the hrHPV types of the same
family. Optimization of PCR and pyrosequencing was performed both on DNA samples and
DNA controls (SiHa and HeLa cell lines; HPV16 and HPV18 synthetic plasmids, Medical Sys-
tem, Genoa, Italy).
Bisulfite modification
The methylation status of a DNA sequence can be determined after DNA treatment with
sodium bisulfite, which deaminates unmethylated cytosine residues on single-stranded DNA
molecules and converts them to uracils, whereas 5-methyl cytosines remain protected from
conversion. DNA polymerase in PCR driven assays converts the uracil residues of bisulfite
modified DNA to thymidines. Different DNA strands, distinguishable by sequencing, are
therefore generated from methylated and unmethylated CpGs.
DNA from clinical samples ( 1 μg), as well as from SiHa and HeLa cell line, used as meth-
ylation positive controls for the HPV16 and HPV18 family respectively, underwent bisulfite
modification using the Epitect Bisulfite Kit (Qiagen) according to the manufacturer’s instruc-
tions, except for the incubation time extended to 16 h, optimized in line with suggestions by
Izzi and coll. [29].
Synthetic HPV16 and HPV18 plasmidic DNA containing the complete genomes (Medical
System, 1 μg) were used as unmethylated controls. These synthetic HPV plasmids were also
used as fully methylated controls after treatment with CpG methylase (M.SssI, Zymo Research,
Irvine, CA, USA) according to the manufacturer’s instructions. Both CpG methylase-treated
and -untreated HPV plasmids underwent two cycles of bisulfite modification with incubation
time extended to 16 h to achieve a complete conversion. Modified DNA was used immediately
or stored at -80˚C until methylation assessment.
Methylation analysis
Methylation assays were performed by pyrosequencing onto a PyroMark Q24 MDx system
(Qiagen). For regions L1 I and L1 II preliminary PCR reactions were performed in a total vol-
ume of 35 μl containing 1X PCR buffer, 2mM MgCl2, 0.8 mM dNTPs, 0.5 μM of each primer,
1.75U Taq polymerase and 2 μl of bisulfte modified DNA. The cycling profile was as follows:
95˚C for 10 min followed by 45 cycles of denaturation at 95˚C for 30 s, annealing for 1 min at
the specific temperature set for each hrHPV type (Table 2), extension at 72˚C for 1 min. Exten-
sion at 72˚C for 10 min was finally performed.
For the L2 region PCRs were performed employing the PyroMark PCR Kit (Qiagen) fol-
lowing manufacturer’s instructions, except for the annealing temperature set for each hrHPV
type as listed in Table 3.
Two μl of bisulfite modified DNA were added to the amplification mix.
HPV methylation by consensus primers-driven pyrosequencing
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Amplicons were analyzed by gel electrophoresis on a 2% agarose gel stained with DNA
intercalating dye (e.g. Syber Safe) and visualized by ultraviolet trans-illumination. Twenty μl of
PCR product were added, in a 24-well microplate, to 60 μl of a mix composed by 18 μl distilled
water, 40 μl binding buffer pH 7.6 (containing 10mM Tris-HCl, 2 M NaCl, 1mM EDTA, 0.1%
Tween 20), and 2 μl of sepharose beads covered by streptavidin, and incubated under shaking.
PCR products were then washed with ethanol 70%, denatured with NaOH 0.2 M and re-
washed with Tris-Acetate 10 mM pH 7.
Pyrosequencing was performed in a total volume of 25 μl, including 24.85 μl of annealing
buffer (20 mM Tris-Acetate, 5 mM MgAc2) and 0.15 μl of 50 μM type-specific sequencing primer
(final concentration 0.3 μM). Assays were created according to the manufacturer’s instructions.
The nucleotide dispensation order was outlined by software Q24 2.0 for each HPV geno-
type. Pyrosequencing reactions were performed in CpG mode (software Q24 version 2.0)
which shows high performance in quantitative evaluation of the proportion of methylated
Table 2. L1 I and L1 II. Primers sequences and annealing temperatures.
Target
Region
HPV type PCR primers and assay conditions Pyrosequencing primers
PCR primer a Ampl.
bp
PCR ann.
T
Sequencinga primer HPV
strand
L1 I b 16,31,33,35,52,58 Forward GATATTTGTAAAAAAATATGGAA
Reverse bio-AATAACTTTTATTTACATCCTAATTAT
78 45 All types
GATATTTGTAAAAAAATATGGAA
Lower
56 Forward TGAAATAGGTGTTGGAGGTAGAT
Reverse bio-
CCCATAATATATATATACAAAAATCCTCCT
143 62 Type 56 GTTATTTGTAAAAAAATAGGGAA Lower
18 Forward TTTATATTGGTATGTAGAAATTTTAGG
Reverse bio-
CCCTATTTTTTTACAAATAACTTTATAAC
229 50 Type 18 TTATAGAAGGTGGTGGAAGAT Lower
39,45,51,59 Forward TTTATATTGATATGAGGATATTTTAGG
Reverse bio-
CCCTATTTTTTTACAAATAACTTTATAAC
229 50 Type 39
AAATATATTATGTTGTTATTAGAT
Type 45 TTATAGAAGGTGGTGGAAGAT
Type 51 ATATATTTTGTTGTTATTAGTG
Type 59
GTAGATATATTTTGTTGTTATTAGA
Lower
L1 II c 16,33,35,52,56,58 Forward GTTAGATATTTTTTTAATAGGG
Reverse bio-ATTACCCCAACAAATACCATTA
207–219 57 Type 16 TGTTGGTGAAAATGTATTAG
Type 33 GGTATATTAGGAGAGGTTGT
Type 35
ATATTTAATAAATTATATTGGTTGT
Type 52 GTTAGATATTTTTTTAATAGGG
Type 56
GAGAATTTTTTTTTAGTTTTGTATA
Type 58 TAGGGTTGGAAAATTTGG
Upper
31 Forward GATGTATAAATATTTAATAAATTA
Reverse bio- ATTACCCCAACAAATACCATTA
75 45 Type 31
GATGTATAAATATTTAATAAATTA
Upper
18,51 Forward GTTTGTAGATTTTTATGGGGATTTTATG
Reverse bio-
ACCAACAAATACCATTATTATAACCCT
266 50 Type 18 ATATATTAAAGGTATAGGTATG Upper
39,45,59 Forward TTGTAAGATATTTTTGGAAT
Reverse bio-
ACCAACAAATACCATTATTATAACCCT
210 55 Type 39 AATTGTATATTAAGGGTA
Type 45
AGATTTATATATTAAAGGTATTAG
Type 51
ATTATTATATTAAGGGTAGTGGTA
Type 59 GTTATATATTAAAGGTATTGA
Upper
a Bisulfite modified sequences
b L1 I. HPV L1 gene. Reference HPV16 CpG: 5601, 5606, 5609, 5616
c L1 II. HPV L1 gene. Reference HPV16 CpG: 6457
https://doi.org/10.1371/journal.pone.0194619.t002
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cytosines at each CpG site through the C/(C+T) ratio [30]. Based on the correspondence of the
sequence to that expected for each genotype and of the quantity of material available, the quality
of the result at each position is classified by the PyroMark CpG mode software as “passed”
(valid/acceptable), “check” (interpretation by operators needed) or “failed” (pyrogram not inter-
pretable). The height of the peak was proportional to the number of sequenced amplicons.
Examples of pyrograms are available in the supplementary data, S1 Fig.
Validation
Consistency with type specific PCR. Comparison was carried out for L1 I and L1 II
regions by testing with the two different assays a total of 90 samples from the pilot project (S1
Table), some of them used for both regions. Comparison was limited to 8 frequent HPV types
(HPV 16, 18, 31, 33, 45, 52, 56 and 58), the seven hrHPV types of the nonavalent vaccine caus-
ing >70% of hgCIN worldwide [31], and the HPV56. The methylation on the L1 I and L1 II
regions was compared separately, considering the mean percentage of CpGs measured as
methylated in each region.
Reproducibility of methylation estimates. We evaluated the protocols performance by
applying the assays to a series of samples (N = 140) from the NTCC Turin cohort that included
long-stored DNA. Half of them had been obtained from cells originally collected not in STM
but in a different transport medium (PreservCyt). Bisulfite modified DNA samples were tested.
To assess the reproducibility of methylation, the procedure was replicated by performing for
Table 3. L2. Primers sequences and annealing temperatures.
Target Region HPV type PCR primers and assay conditions Pyrosequencing primers
PCR primer a Ampl. bp PCR
ann. T
Sequencing a primer HPV strand
L2 b 16 Forward GTTAGGTGGATATGTATTTGTT
Reverse bio- ATACCATTATTTTTAATACATACACATAC
276 58 ATGTTTTATAAAGTTGGG Lower
18 Forward AGGTTGGTTTATATAGTGTATTGT
Reverse bio- ATACCTATACCAAATCCACC
263 56 TTGTATTTTTATAATAAAATTATGG Upper
31 Forward TGGATAAGTATTTGTTGTTTTATATGTT
Reverse bio- CCATTATTTATAATTCATACACATACAT
235 50 TTTGATATAATTGTGTAGTAG Lower
33 Forward GGTTTTGTATGTTTGGTATAGTT
Reverse bio- ACTAATAAATACCTTTATATTTTAACAAT
106 50 GTATAGTTGTGTTGTAGATG Lower
35 Forward TGGATAAGTTTTTGTAGTTTTGTAA
Reverse bio- AATAAATTAATCACATAATATAACCATAC
112 48 TAGTTGTGTTGTAGATG Lower
39 Forward bio- ATAGGTTTTATATAGGTTAGTTGTAGA
Reverse ACCACACCATTAAAAATATTTTATA
226 56 AATAAACATAATTTCCCACC Lower
45 Forward bio- TATGTTTTATATAAGTTAGTTGTAGA
Reverse ACATCCCCATTAACAACATTTACTA
269 56 AACCATAATATCCCACC Lower
51 Forward GTTTTTGGTTTGTTGTTGTAATATTTTAA
Reverse bio- AACCCACTCCACTATAATATTTTATC
87 56 TTGTGATTAAATATGGTGG Upper
52 Forward GTTAGAGGTTTTGTATGTTTGATATAG
Reverse bio- ATTTTCCAATATTTTATATTCACTATCAT
239 50 ATATAGTTGTGTTGTAGAA Lower
56 Forward TTGGATATGTATTAGATAATTTATATGTT
Reverse bio- ACCACATCCTTTTTTAATACATTTATA
209 48 ATATAGTTGTGTTGTAGA Lower
58 Forward GGTTTTGTATGTTTGGTAAAGTT
Reverse bio- CATACACAATACTTAACCCAAC
221 58 GGTAAAGTTGTGTAGTAGA Lower
59 Forward GGGTATGTATTTGTTTGTTTGTAG
Reverse bio-AATACTATATACCCATACAATACTATCC
221 56 AAGTTTGTTGTTGAGG Lower
a Bisulfite modified sequences
b L2. HPV L2 gene. Reference HPV16 CpG: 4261
https://doi.org/10.1371/journal.pone.0194619.t003
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each sample a second PCR run along with the subsequent correspondent pyrosequencing
assay. Again, methylation on the L1 I, L1 II and L2 regions was compared separately, consider-
ing the mean percentage of CpGs measured as methylated in each region and afterwards com-
puting the difference between the mean percent methylation. Because we used residual
modified samples from previous analysis on human genes, some samples did not have suffi-
cient material to perform replicates on all the three target regions. Therefore, replicates on the
L2 region were 105 instead of 140.
Statistical methods
The agreement between the percentage of methylated CpGs measured by testing two aliquots
of the same sample with consensus and type specific primers and that obtained by replicate
testing with consensus primers were evaluated by the intra-class correlation coefficient (ICC).
For this purpose, we used a log transformation of methylation values, so to normalise their dis-
tribution (Shapiro-Wilk test p = 0.55 for type specific and p = 0.21 for consensus primers in
the L1 I region; p = 0.65 and p = 0.69 respectively for the L1 II region). ICC does not assume
different accuracy of compared variables and takes into account systematic differences
between measurements (i.e. considers the alignment on a line with slope = 1). Wilcoxon test
was used to compare methylation levels by cytology groups.
Results
Identification of consensus primers
Sequence variability was found not only among types but also within the same type, and sev-
eral primers had to be designed and tested before setting up the final assays. At first primers
dedicated to each hrHPV type were generated. The sequences of HPV type-specific primers
for the L1 I and L1 II regions, with the corresponding PCR profile, are listed in S2 Table. After-
wards, consensus primers for analysing methylation in the L1 I and L1 II HPV regions were
obtained for groups of hrHPV types within both HPV families (Table 2). For the consensus
primers of L1 I region PCR conditions were identified, working efficiently at annealing tem-
perature of 45˚C for PCR targeting HPV16, 31, 33, 35, 52, 58 of the “16 family”, and of 50˚C
for HPV45, 39, 51, 59 of the “18 family”. With these PCR profiles consensus primers were
however not efficient for HPV56 and HPV18: for those types, dedicated primers and annealing
temperature were maintained.
Similarly, for the L1 II region consensus primers and annealing temperature were set for
PCR targeting HPV16, 33, 35, 52, 56, 58 of the “16 family” and HPV18, 51 and 45, 39, 59 of the
“18 family”. For HPV31 consensus primers were not efficient, and dedicated primers and
annealing temperature were maintained.
Generation of consensus primers for the L2 region was not successful, and dedicated prim-
ers for each HPV type were maintained, along with specific annealing temperatures (Table 3).
Methylation levels for each region and the corresponding PyroMark Q24 score for the 126
tested DNA samples (Pilot project) are reported at supplementary S3 Table. No “failed” score
was assigned by the PyroMark software. “Check” scores were due to a low amount of viral
DNA in the sample, resulting in low peak height. Therefore, they did not spoil the reliability of
the quantitative result or the efficiency of the assay.
Consistency with type specific PCR
A total of 90 samples from the pilot project were tested with two different assays employing
either consensus or type-specific primers in the preliminary PCR preceding pyrosequencing.
HPV methylation by consensus primers-driven pyrosequencing
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The comparison, carried out for L1 I and L1 II regions and limited to types HPV16, 18, 31, 33,
45, 52, 56 and 58, showed a highly comparable quantification of the mean percentage of meth-
ylated CpGs in each region by using the two kinds of primers, with intra-class correlation coef-
ficient between log (methylation) values of 0.97 and 0.99 for L1 I and L1 II respectively (Fig 1
and S1 Table).
Methylation protocol reproducibility
Fig 2 shows the plot of replicate results on the original scale. The intra-class correlation coeffi-
cient between log (methylation) values was 0.94 for the L1 I, 0.87 for the L1 II and 0.97 for the
L2 region. DNA samples gave a 0–4% difference between the two quantitative methylation
results in 123/140 (88%) couples of tests for L1 I, in 108/140 (77%) for L1 II and in 96/105
(91%) for L2 (Fig 3). Therefore, one determination was deemed sufficient to obtain a reliable
result by methylation quantitative analysis when testing the L1 I and L2 regions, whereas two
replicates, taking their average value as final result, were judged to be advisable for the L1 II
region.
Fig 1. Correlation of the percentage of methylation between methylation protocols using consensus or type
specific primers.
https://doi.org/10.1371/journal.pone.0194619.g001
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Fig 2. Correlation of the percentage of methylation between the two replicates for each evaluated hrHPV region.
The same bisulfite modified DNA samples (N = 140) were used to test methylation on HPV L1 I, L1 II and L2 regions.
For L2 regions only 105 had sufficient material for replicates.
https://doi.org/10.1371/journal.pone.0194619.g002
HPV methylation by consensus primers-driven pyrosequencing
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Methylation levels and cytology
Cytology was available for the 126 samples listed in S3 Table. The mean percentage of methyla-
tion was 23,7% for L1 I, 23,7% for L1 II and 22,7% for L2 in HSIL, versus 16,1% for L1 I, 16,1%
for L1 II and 11,5% for L2 in non-HSIL. The difference was statistically significant for L2
(p = 0.0064 by Wilcoxon test) but not for L1 I (p = 0.17) and L1 II (p = 0.24).
Discussion
We sought the feasibility to design consensus primers for hrHPV methylation analysis of all
hrHPV types. Although we targeted the highly conserved HPV capsidic genes, homology
among viral types was not sufficient to allow simultaneous testing of all the twelve hrHPV
types recognized as oncogenic for cervical mucosas. Nevertheless, we succeeded in the genera-
tion of consensus primers able to target two regions on the L1 gene (L1 I and II) for groups of
HPV types, aggregated according to their phylogenetic affinity. Generation of consensus prim-
ers was instead hampered in the L2 region, due to high density of CpGs and low sequence
homology, thus forcing the use of type-specific primers to methylation analyses.
The analytical specificity of the assays newly developed in this study may be in theory
ensured by consistency between the expected sequence to analyse and the resulting pyrogram
for each hrHPV type. Indeed, when targets different from those expected for the specific
genotype were sequenced, failed or confused pyrograms were obtained. To further explore if
the use of our consensus primers could provide results systematically different from those
obtained with type-specific primers we carried out a comparison between the methylation lev-
els measured starting with type-specific primers and with our consensus primers. The very
high agreement obtained supported the analytical reliability of the consensus primers driven
assays.
It must be taken into account that samples of lower quality, having undergone repeated
freeze and thaw episodes, were used to evaluate assays reproducibility. Despite low quality of
these samples, however, good levels of reproducibility of the methylation quantitation by con-
sensus primers were obtained with replicates for the L1 I and L2 regions, with ICC values
Fig 3. Delta methylation percentage between replicates. The same bisulfite modified DNA samples (N = 140) were
used to test methylation on HPV L1 I, L1 II and L2 regions. For L2 regions only 105 had sufficient material for
replicates.
https://doi.org/10.1371/journal.pone.0194619.g003
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above 90%. In addition, the difference between replicates was4% in about 90% of cases.
With such difference, would the average between replicates be calculated, then the difference
between such average and the original results would be2%, an acceptable value in line with
other reports [32]. Reproducibility level was lower for the L1 II region. Therefore, two determi-
nations, with a maximum 4% delta in methylation percentage, seem advisable.
The analytical sensitivity of pyrosequencing allows to target viral DNA also in samples with
low levels of positivity on the original HC2 screening test. The available DNA amount can
marginally affect pyrosequencing results, at most leading to low peaks in the pyrograms, but
does not affect the reliability of the methylation count at the single CpG site analysed. In pre-
liminary PCR for pyrosequencing analyses a minimum of 1–10 ng of DNA is conventionally
used. However, a standardization of DNA amount is not mandatory [33] as pyrosequencing
quantifies the percentage of methylated and unmethylated bases at each position [34]. Indeed,
a consensus on a gold standard method for methylation analyses has currently not yet been
achieved [20,35].
The methylation protocols were developed and set up on DNA from cervical samples stored
for short-time in STM (HPV pilot project sample series) and having undergone only one thaw,
for genotyping assay. Nevertheless, the newly developed protocols showed a good performance
also with the samples from the Turin NTCC biobank, which had a long-time storage and had
been already subjected to multiple freezing and thawing episodes. They performed efficiently
with DNA extracted from cervical cells originally collected and stored either in STM or in Pre-
servCyt transport mediums. Even better efficiency is expected in clinical setting by using fresh
material.
We considered only samples with single HPV infection, as others before [15]. Taking into
account that there is a main interest in testing women with persistent HPV infection, who are
at higher risk to develop hg CIN, this choice was done for several reasons. First, single infec-
tions, when persistent, have higher methylation levels than multiple-type infections [3]. Sec-
ond, single infections by oncogenic types were found in 90% of hgCIN [36] and their
persistence is reported as more frequently resulting in hgCIN and cancer than with multiple
infections [37,38]. Third, methylation protocols using consensus primers could result in over-
lying sequencing and confused pyrograms when multiple types are present. In different stud-
ied cohorts [31,39,40], attribution of HPV types to hgCIN was calculated and top types
highlighted. Our methylation protocols with consensus primers targeting L1 I and L1 II
regions, respectively, would cover with one PCR for each hrHPV family most of the top types
ranked in those studies as prevalent in CIN3.
Our validation of the method was substantially analytical. In a first, very rough, clinical
evaluation, we also compared, in the specimens used for developing and setting up the novel
assays, the methylation value obtained by our method to cytology, an imprecise predictor of
histology. Point estimates suggested an association but, given the small size, the difference was
statistically significant only for one region (L2). In-depth analyses to investigate viral methyla-
tion association with histologically confirmed current or future hgCIN detection have been
conducted in a wide controlled cohort and will be described elsewhere.
Conclusions
This is, to our knowledge, the first attempt to develop consensus primers for multiple HPV
genotypes to use in the assessment of methylation of the L1 and L2 viral regions by pyrose-
quencing in cervical scrape samples.
We designed and set up such primers and the overall procedure, and assessed their analyti-
cal performance in providing a reproducible quantitative estimate similar to that obtained by
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type-specific PCR. Such data show that the developed consensus primers can be considered
equivalent to type-specific primers in order to provide a quantitative evaluation of the methyl-
ation of the considered CpGs by pyrosequencing.
HPV methylation protocols covering the majority of oncogenic types could provide an effi-
cient risk stratification tool to quantify viral methylation in HPV positive women.
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